EcoDrugPlus

Bruton Tyrosine Kinase

Ensembl ID : ENSDCDG00000019556
Gene Symbol: BTK
3 Cross references
204 Possible Orthologues:

C-C Chemokine Receptor Type 9-Like

Ensembl ID : ENSDCDG00000022455
Gene Symbol: LOC114788493
3 Cross references
190 Possible Orthologues:

C-C Chemokine Receptor Type 9-Like

Ensembl ID : ENSDCDG00000000556
Gene Symbol: LOC114782484
2 Cross references
193 Possible Orthologues:

C-X-C Chemokine Receptor Type 4-B-Like

Ensembl ID : ENSDCDG00000002000
Gene Symbol: LOC114790413
3 Cross references
201 Possible Orthologues:

C-X-C Chemokine Receptor Type 4-Like

Ensembl ID : ENSDCDG00000035005
Gene Symbol: LOC114796691
3 Cross references
205 Possible Orthologues:

C-X-C Motif Chemokine Receptor 1

Ensembl ID : ENSDCDG00000027442
Gene Symbol: CXCR1
3 Cross references
275 Possible Orthologues:

Cf Transmembrane Conductance Regulator

Ensembl ID : ENSDCDG00000017451
Gene Symbol: CFTR
3 Cross references
217 Possible Orthologues:

D(1) Dopamine Receptor-Like

Ensembl ID : ENSDCDG00000035021
Gene Symbol: LOC114793045
3 Cross references
201 Possible Orthologues:

D(4) Dopamine Receptor-Like

Ensembl ID : ENSDCDG00000027522
Gene Symbol: LOC114766387
3 Cross references
176 Possible Orthologues:

D(4) Dopamine Receptor-Like

Ensembl ID : ENSDCDG00000028923
Gene Symbol: LOC114767407
3 Cross references
176 Possible Orthologues:

Dna Methyltransferase 1

Ensembl ID : ENSDCDG00000018604
Gene Symbol: DNMT1
3 Cross references
212 Possible Orthologues:

Dna Topoisomerase 1-Like

Ensembl ID : ENSDCDG00000023981
Gene Symbol: LOC114801020
3 Cross references
208 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).